Activity – Page 5

Pfizer Appoints Jeffrey Legos as New Chief Oncology Officer, Bolstering Cancer Drug Development Efforts

4 months ago talkbio0Tagged Antineoplastic Agents, Appointments, Drug Industry, Jeffrey, Leadership, Legos, Neoplasms, Novartis, Pfizer

Pfizer, Jeffrey Legos, oncology, cancer drug development, pharmaceutical industry, Novartis, leadership appointment

FDA Approves Monthly Maintenance Dosing for Eisai and Biogen’s Alzheimer’s Drug Leqembi

4 months ago talkbio0Tagged Alzheimer 's disease, amyloid-beta, Approved, Biogen, dosing, Eisai, Leqembi, Maintenance, Mental deterioration, monthly, United States Food and Drug Administration

Leqembi, Alzheimer’s disease, FDA approval, monthly maintenance dosing, Eisai, Biogen, amyloid-beta, cognitive decline

Sackler Family and Purdue Pharma Agree to Enhanced $7.4 Billion Opioid Settlement

4 months ago talkbio0Tagged addiction, Agreement, Crisis, multistate, Opioids, Pharma, Purdue, Recovery - action, Sackler family

Sackler family, Purdue Pharma, opioid settlement, $7.4 billion, multistate agreement, opioid crisis, addiction treatment, recovery programs

Trump Withdraws US from World Health Organization, Sparking Concerns Over Global Health Security

5 months ago talkbio0Tagged Communicable Diseases, COVID19 (disease), Generalized, health security, Pandemics, public health medicine (field), Transplant Registry Unified Management Program, WHO, Withdraw (activity), World Health Organization

Trump, World Health Organization, WHO, withdrawal, global health security, infectious diseases, pandemics, COVID-19, public health experts.

NVIDIA’s AI Innovations: Pioneering the Future of Artificial Intelligence

5 months ago talkbio0Tagged Accelerated, Aortic Valve Insufficiency, Computation (action), Generative AI, Health care facility, innovations, NVIDIA AI, Robotics

NVIDIA AI Innovations, Generative AI, Accelerated Computing, Robotics, AI in Healthcare, AI Foundation Models

Avalere Health Appoints Amar Urhekar as New CEO to Drive Strategic Growth

6 months ago talkbio0Tagged Amar Urhekar, Appointments, CEO, Health, healthcare strategic partner, Leadership

Amar Urhekar, Avalere Health, CEO appointment, healthcare strategic partner, leadership transition

Strategic Roadmap for Biologics Manufacturing: Enhancing Efficiency and Flexibility

6 months ago talkbio0Tagged Biological Factors, biomanufacturing, bony process, Characterization, Continuous, Efficiency, Manufacturing, Modular Facilities, Pliability, Precision medicines, Regulatory Compliance, Strategic Roadmap, technology roadmap

Biologics manufacturing, Strategic roadmap, Process characterization, Flexibility and efficiency, Regulatory compliance, Biomanufacturing technology roadmap, Precision medicines, Modular facilities, Continuous manufacturing

ASH 2024: Anito-cel Demonstrates Enhanced Response Rate and Consistent Safety in Phase II Update for Relapsed/Refractory Multiple Myeloma

6 months ago talkbio0Tagged 2024, anito-cel, Arcellx, Asymmetric Septal Hypertrophy, Phase II Update, Profiling (action), Rating (action), relapsed/refractory multiple myeloma, Response process, Safety

ASH 2024, Anito-cel, Arcellx, Relapsed/Refractory Multiple Myeloma, Phase II Update, Response Rate, Safety Profile

Controversial Stanford Professor Jay Bhattacharya Nominated by Trump to Lead NIH Amid Criticism Over Pandemic Views

6 months ago talkbio0Tagged Administration occupational activities, Appointments, Bhattacharya, Controversial, COVID19 (disease), Critic, Jay, NIH Director Nomination, Pandemic Response, Professor, Public Health Research, Stanford University, Transplant Registry Unified Management Program

Jay Bhattacharya, NIH Director Nomination, COVID-19 Pandemic Response Critic, Stanford University Professor, Trump Administration, Public Health Research, Controversial Appointment

Halozyme Therapeutics Abandons $2.1 Billion Acquisition Bid for Evotec Due to Lack of Engagement

7 months ago talkbio0Tagged Acquisition, Evotec, Halozyme, Industry, Twice a day, Withdraw (activity)

Halozyme Therapeutics, Evotec, acquisition bid, withdrawal, lack of engagement, biotech industry